Pharmacodynamic effects of nicotine mouth spray and cytisine tablet. A study in adult healthy smokers

Cover Page

Cite item

Full Text

Abstract

The relief of cigarette craving is crucial to increase the success rate of attempts to quit smoking. Temporary relief of cigarette cravings is the therapeutic indication of nicotine replacement therapy. Cytisine is a plant-based alkaloid that is specifically indicated in the management of nicotine dependence. The aim of this open-label, single-dose, randomized, crossover study was to compare the urge-to-smoke in 59 abstinent smokers, who followed an overnight 12-hour nicotine abstinence period, following two consecutive sprays of nicotine mouth spray 1 mg nicotine/spray or one 1.5 mg cytisine tablet on separate treatment days, separated by a washout period of at least 36 hours. Urges to smoke were scored on a visual analogue scale. The results of this study indicate that the onset of relief of urges to smoke following use of nicotine mouth spray 2¥1 mg is substantially and statistically significantly faster than that of cytisine tablet 1.5 mg.

About the authors

Victoria McCaffrey

Consumer Health Products Department, “Consumer Products Department Johnson & Johnson ЕМЕА”

Maidenhead, Great Britain

Anna Hansson

Global Clinical Pharmacology, “McNeil AB”

Email: *ahansson@its.jnj.com
Helsingborg, Sweden

Roland Perfekt

Quantitative Sciences, “McNeil AB”

Helsingborg, Sweden

References

  1. Taggar J.S, Lewis S, Docherty G et al. Do cravings predict smoking cessation in smokers calling a national quit line: secondary analyses from a randomised trial for the utility of “urges to smoke” measures. Subst Abuse Treat Prev Policy 2015; 10: 15.
  2. Piasecki T. Relapse to smoking. Clin Psychol Rev 2006; 26: 196-215.
  3. Swan G, Ward M.M, Jack L.M. Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav 1996; 21 (4): 481-90.
  4. Shiffman S. Refining models of dependence: Variations across persons and situations. Br J Addict 1991; 86: 611-5.
  5. Shiffman S, Hickcox M, Paty J.A et al. Individual differences in the context of smoking lapse episodes. Addict Behav 1997; 22 (6): 797-811.
  6. Fidler J.A, West R. Enjoyment of smoking and urges to smoke as predictors of attempts and success of attempts to stop smoking: a longitudinal study. Drug Alcohol Depend 2011; 115 (1-2): 30-4.
  7. Benowitz N.L. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008; 83 (4): 531-41.
  8. Piper M., Federman E.B, McCarthy D.E et al. Using medication models to explore the nature of tobacco motivation and tobacco treatment effects. J Abnorm Psychol 2008; 117: 94-105.
  9. McCarthy D.E, Piasecki T.M, Lawrence D.L et al. Psychological Mediators of Bupropion SR Treatment for Smoking Cessation. Addiction (Abingdon, England) 2008; 103 (9): 1521-33.
  10. Ferguson S.G, Shiffman S, Gwaltney C.J. Does reducing withdrawal severity mediate nicotine patch efficacy? A randomized clinical trial. J Consult Clin Psychol 2006; 74 (6): 1153-61.
  11. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, D.C.: American Psychiatric Association, 2013; p. 571-7.
  12. Hartmann-Boyce J, Chepkin S.C, Ye W et al. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database Syst Rev 2018; 5: CD000146.
  13. Etter J, Stapleton J.A. Nicotine replacement therapy for long-term smoking cessation: a meta-analysis. Tobacco Control 2006; 15 (4): 280-5.
  14. Wadgave U, Nagesh L. Nicotine Replacement Therapy: An Overview. Int J Health Sci 2016; 10 (3): 425-35.
  15. Garvey A.J, Kinnunen T, Nordstrom B.L et al. Effects of nicotine gum dose by level of nicotine dependence. Nicotine Tob Res 2000; 2: 53-63.
  16. Shiffman S. Use of more nicotine lozenges leads to better success in quitting smoking. Addiction 2007; 102: 809-14.
  17. Tønnesen P, Paoletti P, Gustavsson G et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J 1999; 13 (2): 238-46.
  18. Balmford J, Borland R, Hammond D, Cummings K.M. Adherence to and reasons for premature discontinuation from stop-smoking medications: data from the ITC Four-Country Survey. Nic Tob Res 2011; 13: 94-102.
  19. Hansson A, Hajek P, Perfekt R, Kraiczi H. Effects of nicotine mouth spray on urges to smoke, a randomised clinical trial. BMJ Open 2012; 2: e001618.
  20. Prochaska J.J, Das S, Benowitz N.L. Cytisine, the world's oldest smoking cessation aid. BMJ 2013; 347: f5198.
  21. Jeong S.H, Newcombe D, Sheridan J, Tingle M. Pharmacokinetics of cytisine, an a4 b2 nicotinic receptor partial agonist, in healthy smokers following a single dose. Drug Test Anal 2015; 7 (6): 475-82.
  22. Ravva P, Gastonguay M.R, Faessel H.M et al. Pharmacokinetic-pharmacodynamic modeling of the effect of varenicline on nicotine craving in adult smokers. Nicotine Tob Res 2015; 17 (1): 106-13.
  23. Hansson A, Rasmussen T, Kraiczi H. Single-Dose and Multiple-Dose Pharmacokinetics of Nicotine 6 mg Gum. Nicotine Tob Res 2017; 19 (4): 477-83.
  24. Shiffman S, Hickcox M, Paty J.A et al. Progression from a smoking lapse to relapse: prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996; 64 (5): 993-1002.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).